LiGeR-HN1: what clinicians are saying
petosemtamab plus pembrolizumab in first-line PD-L1+ recurrent or metastatic HNSCC · NCT06525220 ↗ · Phase 3 · Genmab
A surgical oncologist reads LiGeR-HN1 favorably because of the reported size of its survival effect, but questions its position alongside pembrolizumab plus chemotherapy. In earlier treatment-selection context, the clinicians cited weigh symptoms and PD-L1 CPS; one medical oncologist considers monotherapy reasonable for low symptom burden when minimizing toxicity is a priority. Full results remain awaited to clarify absolute survival gains, HPV-specific effects and adverse-event rates.
Abstract written by AI and checked by automated review.
- edition 1
- commentary last checked (automated) Nov 8, 2026 UTC
- Deep size: 321 verified statements (Deep is 301+)
- 182 from 6 clinicians confirmed against the NPI registry or a staff page
More on: Head and neck squamous cell carcinoma, pembrolizumab
This edition $1,950: licensed permanently for your organization's internal use, with MCP access for your AI agent. Use reports inside your organization. You may quote short excerpts anywhere, with attribution and a link. Don't publish or share the report itself, or large parts of it, outside your organization. Buy now · Team and enterprise access
8 findings, and what sits behind each
01. Commentators welcome the survival signal; one clinician asks how it compares with pembrolizumab plus chemotherapy
1 of 6 cited clinicians · 9 statements from 2 speakers in 9 sources · 9 passages
Limitations recorded: 2.
Draws on: The comparison, Primary endpoint: Overall Survival (OS), Population and setting.
02. Clinicians condition trial consideration on resectability; one favors a chemotherapy-containing control for high symptom burden
4 of 6 cited clinicians · 33 statements from 4 speakers in 5 sources, all podcasts or videos · 20 passages
Limitations recorded: 4.
Draws on: The comparison, Population and setting.
03. Clinicians welcome early EGFR activity; one makes future first-line use conditional on phase III confirmation
3 of 6 cited clinicians · 19 statements from 3 speakers in 6 sources, 5 of them podcasts or videos · 12 passages
Limitations recorded: 4.
Draws on: Secondary endpoints, The comparison, Design and conduct.
04. Speakers and accounts seek HPV detail; one account predicts reliable efficacy only in HPV-negative disease
4 of 6 cited clinicians · 27 statements from 7 speakers in 7 sources, 3 of them podcasts or videos · 15 passages
Limitations recorded: 5.
Draws on: Population and setting.
05. Accounts credit the survival endpoint but say the absolute benefit cannot yet be sized
No named clinician · accounts and unnamed speakers · 31 statements from 2 speakers in 7 sources · 8 passages
Limitations recorded: 4.
Draws on: Primary endpoint: Overall Survival (OS), Primary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR), Design and conduct, Secondary endpoints, Safety and tolerability, The comparison.
06. One clinician regards infusion reactions as manageable while stressing administration precautions and schedule differences
2 of 6 cited clinicians · 16 statements from 2 speakers in 9 sources, 4 of them podcasts or videos · 14 passages
Limitations recorded: 5.
Draws on: Safety and tolerability, Primary endpoint: Overall Survival (OS), Secondary endpoints.
07. One clinician conditionally favors upfront EGFR combinations; another asks whether response and PFS gains translate into lasting benefit
4 of 6 cited clinicians · 15 statements from 4 speakers in 5 sources, 4 of them podcasts or videos · 10 passages
Limitations recorded: 4.
Draws on: Secondary endpoints, Population and setting.
08. Accounts offer differing, conditional readings of competing development routes
No named clinician · accounts and unnamed speakers · 37 statements from 4 speakers in 12 sources · 16 passages
Limitations recorded: 5.
Draws on: The comparison, Design and conduct, Primary endpoint: Overall Survival (OS), Population and setting, Safety and tolerability.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 8
1 of 6 cited clinicians
Commentators welcome the survival signal; one clinician asks how it compares with pembrolizumab plus chemotherapy
9 statements from 2 speakers in 9 sources
- 9
- statements
- 9
- passages
- 9
- sources
- 2
- speakers
What the statements areViews 6Questions and uncertainty 1Clinical experience 0Comparisons 2Restated results and context 0Statement-to-passage links (a passage can back several statements)Supporting a statement 11Giving context 1Recorded with the findingLimitations: 2
9 posts and articles
Draws on: The comparison, Primary endpoint: Overall Survival (OS), Population and setting.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
The full report also has 2 findings about other patients, lines of treatment or settings, after these trial findings under “Beyond the trial population”. They are not counted or listed on this page.
Physician, ex-US, identity checked against a staff page · podcast · Jul 2026 · finding 2
A physician sees a good opportunity to offer pembrolizumab plus a non-chemotherapy drug, particularly because the tumor is oral cavity and p16 negative, a disease profile they believe could potentially benefit from EGFR-targeted therapy.
Physician, US, identity checked against NPI · podcast · May 2026 · finding 3
A physician considers emerging anti-EGFR strategies particularly exciting for HPV-negative disease, describing a foundation of studies combining cetuximab with pembrolizumab or nivolumab that showed better response rates and progression-free survival than historical pembrolizumab controls, particularly in HPV-negative patients.
Medical oncologist, US, identity checked against NPI · podcast · Mar 2026 · finding 4
A medical oncologist awaits the phase III petosemtamab findings in HPV-positive disease.
Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.
Abbreviations BICR, blinded independent central review; CPS, combined positive score; EGFR, epidermal growth factor receptor; HCP, healthcare professional; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; ORR, objective response rate; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors.
The full LiGeR-HN1 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians still need to see to compare petosemtamab plus pembrolizumab with pembrolizumab plus chemotherapy in first-line PD-L1-positive recurrent or metastatic HNSCC, given LiGeR-HN1’s pembrolizumab-alone control?
From finding F1 (9 statements from 2 speakers in 9 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 76commentary sources screened
- 37sources cited by verified statements
- 16named in screened sources
- 16speakers cited in the report
- 6cited speakers with a verified identity
6 cited clinicians, speakers with a confirmed clinical role, of them 6 physicians. By role and specialty:
- 3 physician
- 2 physician, Medical oncology
- 1 physician, Surgical oncology
Also in the sources: 9 organizational or shared accounts, not counted as people.
- 321verified statements, each linked to its source
- 182of them from speakers with a confirmed clinical role
- 8findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 321 | Paid |
| Who said each statement, with each cited speaker's role and what confirmed it (NPI registry or staff page) | 16 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 37 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
| Verified speaker IDs as data (NPI, social and scholarly IDs) | 6 | 12-month plan add-on |
Every edition names who said each statement, with MCP access for your AI agent. The verified speaker identities add-on, sold with 12-month plans, adds each verified person's IDs as data (NPI, X, Bluesky, LinkedIn, ORCID, institutional pages) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
14 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Overall Survival (OS) | 17 | 8 |
| Primary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR) | 14 | 6 |
| Secondary endpoints | 7 | 7 |
| Population and setting | 29 | 8 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 31 | 13 |
| Safety and tolerability | 14 | 9 |
| Design and conduct | 11 | 6 |
| Biological rationale and earlier clinical evidence | 17 | 5 |
| Biomarker work-up and limits of treatment-selection shortcuts | 22 | 5 |
| Salvage feasibility and the local-versus-systemic decision | 19 | 3 |
| Upfront intensification, post-progression treatment and sequencing | 22 | 3 |
| Administration, supportive care and multidisciplinary readiness | 19 | 5 |
| Competitive evidence thresholds and conditional development consequences | 37 | 12 |
| Frontline treatment-selection context from HNSCC: Current and Emerging Therapeutic Strategies | 5 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
321 verified statements from 37 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 201 statements · 63%from 6 videos and episodes · about 34 per source | ||||
| YouTube | 78 | 3 | 4 | |
| Podcasts | 123 | 3 | 3 | |
| Posts · 112 statements · 35%from 29 posts · about 4 per source | ||||
| X threads | 110 | 28 | 59 | |
| LinkedIn posts | 2 | 1 | 2 | |
| Bluesky threads | 0 | 0 | 8 | |
| Primary sources · 8 statements · 2%cited for context, not screened · from 2 sources · about 4 per source | ||||
| Publications | 7 | 1 | — | |
| Registry | 1 | 1 | — | |
Bar = statements. A statement drawn from two sources counts half to each. How we sourced and checked this
max 56 / quarter
- Screened window
- Sep 30, 2024 → Nov 6, 2026
- Cited window
- Dec 2, 2024 → Nov 2, 2026
- Retrieved
- Nov 8, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma
- Registry
- NCT06525220
- Study IDs
- MCLA-158-CL03 (GCT1158-03) · 2023-510323-30-00
- Sponsor
- Genmab
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 699 actual
- Registered
- 2024-07-29
- Start
- 2024-09-25 actual
- Primary completion
- 2028-01 estimated
- Primary endpoint
- Overall Survival (OS)
- Interventions
- 2 registered
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on uncertain disease-control benefits of an alternative pembrolizumab combination in HPV-negative head and neck cancer; a view on dissent and anecdotal evidence when weighing immunotherapy doublets against single-agent treatment.
- 2 more clinician views in the sources used in this report are not yet captured as evidence in this edition.
- 1 passage in 1 source used in this report was not fully assessed for clinician views, so a view there may be missing from this edition.
- 169 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
Show all 16 known gaps +Fewer −
- Further source limits: 15 sources about other trials or topics are not included; discussion that uses 3 names the trial shares with other things, without the trial's condition or setting, may be missing.
- The sources reviewed for this edition are not a representative sample of HCP opinion. Social accounts, analyst relays and company-announcement summaries must not be counted as independently confirmed clinical consensus.
- Repeated podcast/video versions and near-identical posts can represent the same discussion or author rather than additional independent agreement.
- Discussion that does not name the trial or uses different transcription variants may be missing. One additional passage was not fully assessed, and a separate passage could not support a named attribution.
- Some passages cannot be assigned to a named speaker. They remain commentary from the relevant discussion and cannot establish agreement or disagreement between additional people.
- Clinical roles for several named social authors and accounts are unknown or unconfirmed. A source's description of someone as MD is attributed source wording, not independent confirmation.
- Phase III results discussed here are company-reported topline information relayed through commentary. Arm-level absolute outcomes, follow-up, event counts, detailed safety and quantitative subgroup results remain necessary for a fuller reading.
- Earlier phase II cohorts, later-line monotherapy findings, historical controls and personal numerical estimates cannot be substituted for LiGeR-HN1 outcomes or direct comparisons.
- No registry protocol file or exact product labels were available to check every design or approval description. The journal protocol describes planned methods rather than observed phase III results.
- Publication, post and repost dates do not establish a session date, a readout presentation date or a speaker's change of mind.
- Some connected discussion is incomplete: HPV-negative interpretations and an HPV-positive biological hypothesis for INBRX-106, the full alternative-agent durability comparison, an alternative combination's population-specific biological rationale, an episode's precise eligibility wording, and qualifications concerning immunotherapy after PD-1 failure are not fully represented. These summaries should not be treated as complete accounts of those exchanges.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 1 fix (names, counts, text)
None of these changed a statement, finding or source.
- Nov 9, 2026 UTCThe trial's name is spelled as its investigators write it, “LiGeR-HN1” (NCT06525220), outside quotations (was “LEGER”, “LIGAR”, “LIGER”, “LIGHER”, “Liger”).
Last checked for new commentary Nov 8, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. LiGeR-HN1 (NCT06525220): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 8, 2026. https://www.erudio.com/reports/liger-hn1-nct06525220
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "LiGeR-HN1" (NCT06525220), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "liger-hn1-nct06525220". If you cannot make requests, read https://www.erudio.com/reports/liger-hn1-nct06525220.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06525220", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06525220 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/liger-hn1-nct06525220.json
curl https://www.erudio.com/reports/liger-hn1-nct06525220.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "liger-hn1-nct06525220" })release bf5c3b240be60d0a85cbe7a605402ecd4b70bcfb1556960dac9cd47bf9b33325